EVH· Health Care› Health Information Services

Evolent Health, Inc Class A

Stage 3 · Topping · week 7

As of Oct 22, 2026, Evolent Health is in Stage 3, the topping phase, now in week 7 (since Sep 9, 2026). It closed at $4.89, 39.5% below its 52-week high and above its 200-day average, which is rising.

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. More about the company

$4.89

+1.24% today

$553M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is EVH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 15w

S4 34w

S4 33w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 13w → S1 8w → S2 15w → S3 3w → S4 12w → S1 7w → S2 4w → S3 1w → S4 34w → S1 8w → S2 1w → S1 1w → S4 33w → S1 9w → S2 6w → S3 2w → S2 1w → S3 6w current

Total tracked: 164 weeks across 18 stage runs.

EVH among Health Information Services23rd of 41 by relative strength

All 41 →

Stocks in Health Information Services ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	AMWLAmerican Well Corporation Class A	Stage 2 · wk 25	97	+7.4%
2	HNGEHinge Health, Inc. Class A	Stage 2 · wk 20	96	+19.1%
3	BTSGBrightSpring Health Services, Inc.	Stage 3 · wk 8	94	+9.1%
4	NRCNRC Health	Stage 3 · wk 4	93	−0.1%
5	SOPHSOPHiA GENETICS SA	Stage 2 · wk 24	91	−12.7%
6	HTFLHeartflow, Inc.	Stage 2 · wk 10	87	+17.0%
7	HSTMHealthStream, Inc.	Stage 2 · wk 17	77	+20.3%
8	OMCLOmnicell, Inc.	Stage 4 · wk 10	70	+12.5%
…23	EVHEvolent Health, Inc Class A	Stage 3 · wk 7	28	+35.1%

vs 52W High

-39.5%

$2.17 lo$8.08 hi

39.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 7

1w13w26w

Week 7, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

26.7%

200 DMA: $3.86 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.55x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+35.1%

+15.9%

+65.8%

YTD

+25.7%

-40.2%

Scan Membership

Breakout Watch

Latest: 2024-10-04

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 7 · Vol 0.55x

2026-10-21S3

Wk 7 · Vol 0.53x

2026-10-20S3

Wk 6 · Vol 0.47x

2026-10-19S3

Wk 6 · Vol 0.64x

2026-10-16S3

Wk 6 · Vol 0.78x

2026-10-15S3

Wk 6 · Vol 1.45x

2026-10-14S3

Wk 6 · Vol 0.85x

2026-10-13S3

Wk 5 · Vol 0.96x

2026-10-12S3

Wk 5 · Vol 0.43x

2026-10-09S3

Wk 5 · Vol 0.38x

2026-10-08S3

Wk 5 · Vol 1.02x

2026-10-07S3

Wk 5 · Vol 0.96x

Moving averages & range

50 DMA

$4.22

200 DMA

$3.86

52W High

$8.08

52W Low

$2.17

5D Low

$4.48

Resistance levels (recent highs)

20d High

$4.89

60d High

$4.92

120d High

$6.19

250d High

$7.81

Next resistance

+0.6%

to 60d High

ROE

-67.0%

Profit margin -24.1%

Dividend Yield

0.00%

P/B 1.4

Evolent Health: quick answers

What stage is Evolent Health in?

As of Oct 22, 2026, Evolent Health (EVH) is in Stage 3, the topping phase. It entered Stage 3 on Sep 9, 2026 and is in week 7. What the four stages mean

Is Evolent Health in an uptrend?

Its uptrend has stalled. Evolent Health is in Stage 3, the topping phase that follows an advance. It trades 26.7% above its 200-day average, which is rising.

How far is Evolent Health from its 52-week high?

Evolent Health closed at $4.89 on Oct 22, 2026, 39.5% below its 52-week high of $8.08. Its 52-week low is $2.17.

How has Evolent Health performed over the past year?

As of Oct 22, 2026, Evolent Health is down 40.2% over the past year and up 25.7% so far in 2026.

Which sector and industry is Evolent Health in?

Evolent Health is in the Health Information Services industry, part of the Health Care sector.

About this companyHealth Care· Health Information Services

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.